Intech Biopharm Ltd (6461) - Total Liabilities

Latest as of September 2025: NT$1.51 Billion TWD ≈ $47.53 Million USD

Based on the latest financial reports, Intech Biopharm Ltd (6461) has total liabilities worth NT$1.51 Billion TWD (≈ $47.53 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Intech Biopharm Ltd cash conversion from operations to assess how effectively this company generates cash.

Intech Biopharm Ltd - Total Liabilities Trend (2017–2024)

This chart illustrates how Intech Biopharm Ltd's total liabilities have evolved over time, based on quarterly financial data. Check asset resilience ratio of Intech Biopharm Ltd to evaluate the company's liquid asset resilience ratio.

Intech Biopharm Ltd Competitors by Total Liabilities

The table below lists competitors of Intech Biopharm Ltd ranked by their total liabilities.

Company	Country	Total Liabilities
Fullerton Technology Co Ltd TW:6136	Taiwan	NT$363.19 Million
Korea Flange KO:010100	Korea	₩611.10 Billion
Insumos Agroquimicos SA BA:INAG	Argentina	AR$39.89 Billion
Munsin Garment TWO:2916	Taiwan	NT$606.48 Million
Y-Entec Co. Ltd KQ:067900	Korea	₩152.37 Billion
Hainan Airlines Co Ltd B SHG:900945	China	$140.66 Billion
Raisio Oyj HE:RAIKV	Finland	€64.30 Million
Cytogen Inc KQ:217330	Korea	₩26.25 Billion

Liability Composition Analysis (2017–2024)

This chart breaks down Intech Biopharm Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Intech Biopharm Ltd stock valuation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	1.28	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	1.53	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.60	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Intech Biopharm Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Intech Biopharm Ltd (2017–2024)

The table below shows the annual total liabilities of Intech Biopharm Ltd from 2017 to 2024.

Year	Total Liabilities	Change
2024-12-31	NT$1.58 Billion ≈ $49.83 Million	+2.48%
2023-12-31	NT$1.54 Billion ≈ $48.62 Million	+1.61%
2022-12-31	NT$1.52 Billion ≈ $47.85 Million	+20.16%
2021-12-31	NT$1.26 Billion ≈ $39.82 Million	-2.22%
2020-12-31	NT$1.29 Billion ≈ $40.73 Million	+24.70%
2019-12-31	NT$1.04 Billion ≈ $32.66 Million	+1.20%
2018-12-31	NT$1.02 Billion ≈ $32.27 Million	+15.42%
2017-12-31	NT$887.48 Million ≈ $27.96 Million	--

About Intech Biopharm Ltd

TWO:6461 Taiwan Biotechnology

Market Cap

$92.41 Million

NT$2.93 Billion TWD

Market Cap Rank

#19483 Global

#1118 in Taiwan

Share Price

NT$17.90

Change (1 day)

-0.56%

52-Week Range

NT$14.40 - NT$25.05

All Time High

NT$57.64